ImmunityBio: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
ImmunityBio (NASDAQ:IBRX) reported Q4 earnings with an EPS of $-0.38, missing estimates by -111%, and a revenue increase of $66 thousand from the previous year. Last quarter, the company beat EPS estimates, resulting in a 9.0% share price increase the following day.
March 19, 2024 | 9:25 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ImmunityBio reported a significant miss in Q4 earnings with an EPS of -$0.38 against an estimate of -$0.18, but saw a revenue increase of $66 thousand YOY.
The significant miss in earnings estimates is likely to negatively impact investor sentiment and stock price in the short term, especially considering the positive reaction to last quarter's earnings beat. However, the increase in revenue YOY may provide some buffer against a steep decline.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100